A tyrosine-sulfated CCR5-mimetic peptide, CCR5mim1, inhibits HIV-1 infection more efficiently than sulfopeptides based on the CCR5 amino terminus. Here we characterized sulfopeptide chimeras of CCR5mim1 and the heavy-chain CDR3 of the antibody PG16. Two chimeras bound a range of envelope glycoproteins and neutralized HIV-1 more efficiently than CCR5mim1. An immunoadhesin form of one of these, CCR5mim2-Ig, synergized with CD4-Ig to neutralize HIV-1. These sulfopeptides are among the broadest and most potent CCR5-mimetic peptides described to date.
H
uman immunodeficiency virus type 1 (HIV-1) entry requires cellular expression of CD4 and a coreceptor, principally CCR5 or CXCR4 (1, 5, 11) . Virion association with CD4 triggers conformational changes in the HIV-1 envelope glycoprotein gp120 that promote high-affinity association with the coreceptor (21, 23 ). An acidic, tyrosine-sulfated region of the CCR5 amino terminus is critical for gp120 association, and most or all functional HIV-1 and simian immunodeficiency virus (SIV) coreceptors have amino termini bearing multiple sulfotyrosines (7) (8) (9) . These sulfotyrosines interact with conserved pockets in the C4 region and at the base of the V3 loop of HIV-1 gp120 (3, 4, 10, 12) . Coreceptor-binding site antibodies with tyrosine-sulfated antigen-combining regions also bind these conserved pockets, including E51, the most potent of the CD4-inducible (CD4i) HIV-1 neutralizing antibodies (2, 12) . Recently, two additional broadly neutralizing antibodies, PG9 and PG16, have been identified (22) . Like E51, these antibodies include sulfotyrosines in their heavy-chain CDR3. However, unlike CD4i antibodies, their association with the HIV-1 envelope glycoprotein is not enhanced by CD4.
Sulfopeptides based on the sequence of the CCR5 amino terminus specifically bind gp120 and inhibit HIV-1 entry, but only at 50 to 100 M concentrations (4, 10) , precluding their use as therapeutics. A mimetic peptide derived from the heavy-chain CDR3 of E51, p⌬E51 (CCR5mim1), associates with gp120 with higher affinity and more efficiently neutralizes HIV-1 entry (6, 14) . CCR5mim1 retains the arrangement of CCR5 sulfotyrosines, but it outperforms CCR5-based peptides, likely because it is more flexible and soluble than CCR5-based peptides.
The example of CCR5mim1 suggested that additional antibody-derived peptides may bind gp120 more broadly and efficiently than either CCR5-based peptides or CCR5mim1. Accordingly, we investigated whether pPG16, a peptide based on the heavy-chain CDR3 region of PG16 (Fig. 1A) , could precipitate gp120 using a previously described assay. We observed that pPG16-Ig, a fusion of this peptide with the human IgG1 Fc domain, bound metabolically labeled consensus B and C gp120 less efficiently than CCR5mim1-Ig (Fig. 1B) . However, two pPG16-Ig variants precipitated similar amounts of consensus B gp120 and greater amounts of consensus C gp120 (Fig. 1B) . Both variants included a phenylalanine-to-tyrosine substitution. We subsequently focused on variant 4 (pPG16v4-Ig) with this substitution alone (Fig.  1A) . Unlike a single-chain form (scFv) of the PG16 antibody, binding of pPG16v4-Ig to consensus C gp120 was enhanced by soluble CD4 (sCD4) (Fig. 1C) . Also, pPG16v4-Ig could incorporate more [ 35 S]sulfate than wild-type pPG16-Ig, suggesting that the newly introduced tyrosine was modified by sulfate (Fig. 1D) .
CCR5mim1, pPG16v4, and CCR5 share a arrangement of sulfotyrosines, facilitating their alignment. Based on this alignment, seven chimeras (pSwap1 to -7) between CCR5mim1 and pPG16v4 were made as Fc fusions ( Fig. 2A) . Several of these chimeras precipitated consensus B and C gp120 molecules with efficiency comparable to or better than that of either CCR5mim1-Ig or pPG16v4-Ig (Fig. 2B) . We further compared two of these variants, pSwap3-Ig and pSwap7-Ig, with CCR5mim1-Ig and pPG16v4-Ig for their ability to bind a range of cell-surfaceexpressed HIV-1 envelope glycoproteins. In most cases, these variants bound envelope-glycoprotein-expressing cells more efficiently than CCR5mim1-Ig, pPG16v4-Ig, or a control Fc fusion with the sulfopeptide derived from the C5a receptor, pC5aR-Ig (Fig. 3A) . In some cases, these peptides bound poorly, but their association was markedly enhanced by sCD4 (Fig. 3B) . Also, pSwap3-Ig and pSwap7-Ig bound gp120 in the same region as both CCR5 and CCR5mim1, as indicated by their inability to bind consensus B (ConB) gp120 variants altered in a conserved CCR5-binding region (Fig. 3C) (6, 19) . Given its close similarity to CCR5mim1 and its ability to bind envelope glycoprotein with higher affinity, we refer to pSwap7-Ig from this point on as "CCR5mim2-Ig."
Next we analyzed pC5aR-Ig, CCR5mim1-Ig, pSwap3-Ig, and CCR5mim2-Ig using a previously described entry inhibition assay (6, 10) . Both pSwap3-Ig and CCR5mim2-Ig neutralized the dualtropic, clade B isolate 89.6 more efficiently than CCR5mim1-Ig, with 50% inhibitory concentrations (IC 50 s) of approximately 10 nM (Fig. 4A) . They better neutralized consensus B and C isolates, but with IC 50 s of approximately 4 M (Fig. 4B ). Using a previously described TZM-bl cell neutralization assay (16), we next investigated the ability of CCR5mim2-Ig to enhance CD4-Ig-mediated neutralization of HIV-1. When total protein was kept constant at the IC 50 of CD4-Ig alone, a 9:1 ratio of CD4-Ig to CCR5mim2-Ig (4.5:1 on a molar basis) neutralized all pseudoviruses assayed more efficiently than CD4-Ig alone (Fig. 4C) . This effect was evident at a 9:1 ratio for a range of total protein concentrations (Fig. 4D) .
The synergy between CCR5mim2-Ig and CD4-Ig raises the possibility that a CCR5-mimetic peptide such a CCR5mim2 might increase the therapeutic utility of CD4-Ig. Despite its necessary breadth, CD4-Ig has been disappointing therapeutically because it has lower affinity for gp120 than effective neutralizing antibodies and because at low concentrations CD4-Ig enhances rather than inhibits HIV-1 entry (18, 20) . This enhancement may occur because soluble forms of CD4 promote virion association with the coreceptor (21, 23). CCR5mim2-Ig can prevent coreceptor association with the virus and limit this enhancement. CCR5 mimetics like CCR5mim2-Ig have a second property that may also contribute to its potency as a partner for CD4-Ig. Unlike CD4-Ig, both arms of the dimeric CCR5 mimetic immunoadhesin can bind to gp120 monomers of an envelope glycoprotein trimer (14) , perhaps more effectively preventing virus association with the cell. Finally, it is well established and consistent with our data here that sCD4 and CD4-Ig markedly enhance gp120 association with CCR5-mimetic peptides (4, 6, 10) . We have also shown that in some cases, CCR5-mimetic peptides can decrease the off rate of CD4-mimetic peptides (14) and perhaps CD4-Ig from the envelope glycoprotein.
Combinations of CD4-and CCR5-mimetic peptides have one key advantage over most neutralizing antibodies: they associate with necessarily conserved regions of gp120 (15, 24) . In contrast, antibody epitopes are larger than the CD4-and CCR5-binding sites and so must include variable residues that permit escape. Recent advances in gene therapy, such as self-complementary adeno-associated virus (scAAV), have enabled persistent expression of high levels of immunoadhesins but impose a size limit that precludes expression of full-length antibodies (13, 17) . In contrast, both CD4-Ig and CCR5mim2-Ig can be easily expressed by scAAV vectors. Further study of their use in this context and further improvement of CCR5-mimetic peptides are therefore warranted. Finally, CCR5mim1, CCR5mim2, and pSwap3 may be useful in exploring the variation in the sulfotyrosine-binding pockets of gp120 or investigating the conformational transitions of the HIV-1 envelope glycoprotein.
